• Metavia completed dose titration in Phase 1 Part 3 testing obesity drug candidate DA-1726, with all active patients reaching 48 mg or 64 mg.
• The trial is evaluating one-step titration to 48 mg or two-step titration to 64 mg to improve tolerability at higher doses.
• Topline data remains scheduled for the fourth quarter of 2026.
• Earlier Phase 1 MAD results cited 9.1% mean weight loss at 48 mg over 8 weeks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-082116), on July 09, 2026, and is solely responsible for the information contained therein.